Mississippi Attorney Lawyer

Well, why not we go ahead and get started. Highest is, of course, Wyeth. We are very pleased Bob Essner and Justin Victoria of society. Bob is Chairman, President and CEO, Justin, you all know, it is Vice President, Investor Relations. So, Bob?ROBERT ESSNER, Chairman, President, CEO, Wyeth: Thank you, Scott, and good morning to everyone. It is a pleasure to be here so that you fall a little earlier verification of Wyeth and where we are today, and the progress we have made so far this year and a few of our prospects profits for the remainder of the year and also for the future. It is precisely to recall that a number of things I say today, of course, is focused on future reports, and I’ll remind you, this report, which described. Until now, in the first half of the year, Wyeth became a successful start-up, with a turnover in double figures in all three of our businesses. I think in SG & A of the line, we do a good job to keep our costs under control to lose, but not our market presence and our R & D is up 10 percent, and that is a trend that we assume that, in at least the plan for the years to come, like many objects that we now have at the end of the stage from conception to completion. Our EPS the first half of the year rose by 5 per cent, but we believe we are on track today for our old line of $ 2.60 to $ 2.70 cents per share for 2004 . The growth of our business is much more supplies today by a few large and very attractive product and expenditure, I’ll be a little time for you only aware of everything and each of these five. Effexor is now our primary product with a turnover should be more than $ 3 billion this year. As you all know, the antidepressant the U.S. market was a little on the point now where the overall growth of pocket is relatively flat. The causes of the, probably several, but there is a comparison with the increasing load factor, we saw after 9 / 11, which has significantly slowed. And I think, more than anything else, the negative publicity on the latest trends suicidal young adolescents who, although not all relevant or particularly relevant to the use of Effexor, has something of a cloud, I think on the whole category and reduce the total amount of rules for antidepressants today. Outside the USA, our company to be even stronger than in the States. And today, a number of Effexor antidepressant sales outside the USA. And we worked very hard for this state very well against some competitors in the world. We expect that category to the extent that it is past rebound that we will see better prescription growth for the category as a whole and we believe that Effexor in the future is even more than their fair share of this increase in The category growth. Enbrel, as you know, is a medicine absolutely remarkable that we have in common with the USA Amgen, but only outside the USA. We now have the opportunity to see how Enbrel, in a market where it and its competitors are relatively complete delivery, and we are pleased, very happy to say that we are more convinced than ever that Enbrel is a leader in the category this class . As you know, we (inaudible) psoriatic arthritis. Psoriasis is now the USA, and we hope they will be approved in Europe this year. And we see a pleasant dip in the dermatologist to prescribe Enbrel. We are on the target system to achieve.